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Abstract 
Systematic in-vitro studies have been conducted to determine the ability of a range of 10 
potential hydrotropes to improve the apparent aqueous solubility of the poorly water soluble 
drug, indomethacin. Solubilisation of the drug in the presence of the hydrotropes was 
determined experimentally using high-performance liquid chromatography (HPLC) with 
ultraviolet (UV) detection. These experimental data, together with various known and 
computed physicochemical properties of the hydrotropes were thereafter used in silico to 
train an artificial neural network (ANN) to allow for predictions of indomethacin solubilisation. 
The trained ANN was found to give highly accurate predictions of indomethacin solubilisation 
in the presence of hydrotropes and was thus shown to provide a valuable means by which 
hydrotrope efficacy could be screened computationally. Interrogation of the network 
connection weights afforded a quantitative assessment of the relative importance of the 
various hydrotrope physicochemical properties in determining the extent of the 
enhancement in indomethacin solubilisation. It is concluded that in-silico screening of 
drug/hydrotrope systems using artificial neural networks offers significant potential to reduce 
the need for extensive laboratory testing of these systems, and could thus provide an 
economy in terms of reduced costs and time in drug formulation development. 
 
[Word count: 189; max = 200] 
 
Keywords: artificial neural networks; indomethacin; drug formulation; hydrotropes; drug 
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Chemical compounds studied in this article: 
Indomethacin (PubChem CID: 3715); sodium nicotinate (PubChem CID: 23687810); sodium 
benzoate (PubChem CID: 517055); sodium salicylate (PubChem CID: 16760658); sodium 
gentisate (PubChem CID: 23663629); sodium benzenesulfonate(PubChem CID: 517327); 
sodium p-toluenesulfonate (PubChem CID: 3720192); benzamide (PubChem CID: 2331); N,N-
dimethylbenzamide (PubChem CID: 11916); nicotinamide (PubChem CID: 936); N,N-
diethylnicotinamide (PubChem CID: 5497). 
 
1. Introduction 
The task of optimising drug solubility remains a major concern for the formulator of 
pharmaceutical dosage forms. Approximately 40% of drugs with market approval and almost 
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90% of compounds in the development pipeline fail to reach the market because of problems 
of poor aqueous solubility (Kalepu and Nekkanti 2015, Zhang et al. 2014). It is well known that 
poor aqueous solubility can significantly limit a drug’s bioavailability and ultimately, 
therefore, its efficacy, thereby necessitating the administration of higher doses and increasing 
the chance of side effects as well as costing more per patient (Williams et al. 2013). There are 
numerous formulation strategies that have been proposed and used to overcome this 
problem, and one such strategy involves the use of hydrotropes (Kunz et al. 2016). 
The term of hydrotropy was used to describe the increase of the apparent aqueous solubility 
of insoluble or slightly soluble organic substances in water by the addition of large 
concentrations of some organic acid salts of alkali metal such as sodium benzoate (Neuberg 
1916). Hydrotropes are modestly amphiphilic organic compounds that possess only a 
relatively small hydrophobic moiety which were considered as non-micelle forming 
compounds (Elworthy et al. 1968). Unlike surfactants, however, – which can also be used to 
enhance drug solubilisation – hydrotropes achieve their solubilisation effects only at quite 
high concentration, generally, in the molar rather than the millimolar range (Balasubramanian 
et al. 1989, Hopkins Hatzopoulos et al. 2011). 
The phenomenon of hydrotropy was first recognised by Carl Neuberg back in 1916 (Neuberg 
1916) but there has been relatively little work since that time performed to explore – in a 
detailed and systematic manner – the ability of different hydrotropes to increase the 
apparent (drug) solubility. A variety of mechanisms have been proposed for hydrotropic 
solubilisation including: increased drug solubilisation as the result of hydrotrope self-
aggregate formation (Badwan et al. 1983, Balasubramanian et al. 1989, Cui et al. 2010), 
hydrotrope-induced alteration of the water structure (Coffman and Kildsig 1996), formation 
of solute-hydrotrope complexes (Sanghvi et al. 2007), and more recently, solubilisation driven 
by an accumulation of hydrotrope around the drug (Abbott et al. 2017, Booth et al. 2015, 
Shimizu and Matubayasi 2014). 
As a consequence of our incomplete understanding of the phenomenon, the task of selecting 
an appropriate hydrotrope for a given poorly water-soluble drug is generally approached 
simply by trial-and-error screening of a large number of potential hydrotropic agents. Such 
selection, however, might be much more conveniently made in silico using artificial neural 
networks (ANNs). ANNs are biologically inspired computational models capable of simulating 
the brain’s ability to learn by example; they provide particularly powerful tools to aid in the 
modeling of non-linear relationships and have found numerous applications in the 
pharmaceutical sciences (Gawehn et al. 2016, Marsland 2015, Sutariya et al. 2013). 
In the studies reported here our aim was to explore the potential for using ANNs to predict 
the effects of likely hydrotropic agents on the apparent aqueous solubility of poorly water-
soluble drugs. In order for such in-silico predictions to provide significant benefit to drug 
formulators, the ANN ultimately produced would need to cater for any poorly water-soluble 
drug, and be able to provide reliable predictions of the solubility enhancements achieved 
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using any potential hydrotrope. In the initial studies reported here, however, we aimed only 
to establish proof of principle, seeking only to determine whether an ANN could be trained 
to give reliable predictions of the solubility enhancements achieved using different 
hydrotropic agents for just a single drug. The drug chosen for the studies was the non-
steroidal, anti-inflammatory agent, indomethacin (Figure 1). This particular drug was chosen 
in part because of the interest in producing aqueous formulations for injection and 
ophthalmic use (Elsaman and Ali 2016, Halim Mohamed and Mahmoud 2011, Sostres et al. 
2013), and partly because there have been some experimental studies reported in which 
hydrotropes have been explored as a means to improve its aqueous solubility (Jain 2008). 
Experimental data were obtained on the solubilisation of the drug using a systematically 
chosen range of 10 potential hydrotropes, each possessing a simple (phenyl or pyridinyl) 
aromatic hydrophobe and a hydrophilic group comprising a carboxylate, sulfonate, or amide 
moiety. The chosen compounds included, sodium nicotinate, sodium benzoate, sodium 
salicylate, sodium gentisate, sodium benzenesulfonate, sodium p-toluenesulfonate, 
benzamide, N,N-dimethylbenzamide, nicotinamide, and N,N-diethylnicotinamide (Figure 2). 
The drug solubilisation data obtained were taken along with various known and computed 
physicochemical descriptors of the hydrotropes and were used to train an ANN to allow for 
prediction of new hydrotropes for indomethacin. 
2. Materials and methods 
2.1. Chemicals and Reagents 
Indomethacin (purity ≥99%, confirmed as the λ polymorph, and used as received), sodium 
nicotinate, sodium benzoate, sodium salicylate, sodium gentisate, sodium benzenesulfonate, 
sodium p-toluenesulfonate, benzamide, N,N-dimethylbenzamide, nicotinamide, N,N-
diethylnicotinamide, pyridoxine, and formic acid were all purchased from Sigma-Aldrich Ltd. 
(Dorset, U.K.). Caffeine was supplied from Alfa Aesar (Lancashire, U.K.). Both water and 
acetonitrile were HPLC-grade and were obtained from Fisher Scientific UK Ltd. (Leicestershire, 
U.K.). All chemical reagents were ≥95% pure and used as received. Water at 18.2 mΩ.cm (25 
oC) was purified by an ultra-pure water system (ELGA, UK). 
2.2. Instrumentation and chromatographic conditions 
Chromatographic analysis of indomethacin was performed using an HP 1050 series liquid 
chromatography system (Agilent Technologies, UK), equipped with HP 1050 quaternary 
pump, DAD detector, autosampler, and column oven, and a G1379A vacuum degasser. The 
system was controlled by ChemStation Software (version A10.02). Chromatography was 
performed using an XTerra 3.5 μm C18 column, 2.1 mm ID X 150 mm length (Waters, Milford, 
USA). The mobile phase was 45:55% (v/v) acetonitrile:water with 0.1% formic acid at a flow 
rate of 0.3 mL/min. The injection volume was 5 µL and the wavelength set at 320 nm. All 
measurements were made in triplicate and averaged for all experiments. The total run time 
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for each analysis was 10 min. Under the conditions described, the measured retention time 
for indomethacin was 7 min and not influenced by the presence of hydrotrope. 
2.3. Working standard solution and sample preparation 
A standard solution of indomethacin dissolved in the mobile phase was prepared at a 
concentration of 100 µg/mL. The standard solution was further diluted in the mobile phase 
to obtain 2.5, 5, 7.5, 10, and 12.5 µg/mL solutions which were used for calibration. Each 
dilution was prepared in triplicate and Beer’s law was obeyed in this concentration range 
(r2=0.999). 
Different concentrations of the 10 hydrotropes were prepared in ultrapure water (with 
uncertainties in the measured concentrations  1%). Excess indomethacin was added to 
microfuge tubes containing different concentrations of each hydrotrope (n = 9, i.e., 3 
concentrations tested on 3 different occasions).  To reach equilibrium, the aqueous solutions 
were prepared at ambient temperature (22 +/- 2 oC) and mixed by affixing the tubes to a 
circular rotating wheel with rotation carried out for 24, 48 and 72 h. Tubes were covered with 
aluminium foil to avoid any possibility of photochemical reaction. At each time interval, 3 
tubes/concentration were removed and centrifuged for 15 minutes at 13000 rpm (using an 
Heraeus Biofuge Pico D-35720; Germany) and the supernatant then transferred into fresh 
tubes and re-centrifuged under the same conditions, to ensure removal of the excess 
indomethacin. Note, that preliminary studies indicated that no difference in the apparent 
aqueous solubility of indomethacin was obtained if the excess drug was removed by filtration 
through 0.22 µm polyethersulfone filters (Jet Biofiltration Co. Ltd, China). Furthermore, the 
form of the excess indomethacin in the solubility experiment was confirmed to be the gamma 
form by means of melting point determination. The pH of the indomethacin, hydrotrope, and 
indomethacin-hydrotrope solutions was measured in triplicate at ambient temperature (22 
+/- 2 oC) by means of pH meter (Jenway-3505, UK).  
The prepared mixtures of indomethacin/hydrotrope were diluted with the mobile phase to a 
concentration falling within the calibration range and the dissolved indomethacin quantified 
by HPLC-UV as a function of each hydrotrope concentration. In addition, as equilibrium was 
achieved by 24 h, all results after 24, 48 and 72 h were averaged and the values reported 
below represent the mean ± standard deviation (n ≥ 8). 
2.4. Artificial neural network structure, training, and usage 
Implementation and training of a feed-forward back-propagation artificial neural network 
(ANN) (Rumerhart et al. 1986) were carried out using the Windows© version (Nazir et al. 
2002) of the PUDDLE software (Richardson and Barlow 1996). A network consisting of an 
input, two hidden, and an output layer, with 10, 2, 2, 1 neurons, respectively, was found 
adequate for predicting the aqueous solubility of indomethacin as a function of various 
hydrotrope properties and varying hydrotrope concentrations. The network topology and 
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learning parameters (i.e., network momentum, noise level, weight and bias range) were 
varied to optimise training performance and prediction accuracy. ANN training was carried 
out using batch-processing of the input data, and employing a sigmoid activation function, 
with the time-invariant noise algorithm (TINA) (Robert et al. 1992) to avoid trapping in local 
minima. 
The parameters chosen as inputs to the ANN were selected so that all were readily 
interpretable in structural terms, and all determined by simple inspection of the chemical 
structures of the hydrotropes or else reliably predicted using readily available computational 
tools and/or web resources. Pilot studies were carried out using a set of 12 physicochemical 
descriptors, and two of these (molecular weight and aqueous solubility) were found to make 
little contribution in the ANN training. The descriptors that were ultimately used in ANN 
training included: hydrotrope concentration, melting point, logP, pKa, hydrogen bond donor 
count, hydrogen bond acceptor count, heavy atom count, complexity, fraction ionised (pH 
6.6), and acid/base species (-1, 0, and +1 for acidic, neutral and basic compounds, 
respectively). The logP values used for the acidic hydrotropes that were studied 
experimentally as sodium salts were taken as those of the parent acids.  
Values of the melting point, logP, and pKa were determined utilizing EPI suiteTM software 
(EPIsuiteTM 2008) unless otherwise stated. The remaining properties of hydrogen bond donor 
count, hydrogen bond acceptor count, and complexity were obtained from the NCBI 
PubChem Database (Kim et al. 2015). All input parameters were normalised to the range 0-1, 
and the ANN training and cross-validation performed using 35 and 8 datasets, respectively 
(Table 1a-b). 
The partitioning of the input between the training and cross-validation datasets was made in 
such a way that the examples used in training defined the limits of the parameter space to be 
explored, with the cross-validation input patterns then chosen so that they sampled within 
and across this space, involving a selection of hydrotropes from the same series used in 
training (and with varying hydrotrope concentrations), and with the addition of caffeine – a 
widely-used hydrotrope (Cui 2010, Lee et al. 2003) – serving as an external test compound by 
which to judge the ability of the trained ANN to generalize. 
 
3. Results and discussion 
3.1. In-vitro screening of potential hydrotropes for indomethacin  
The baseline aqueous solubility of indomethacin was determined as 2.8 ± 0.4 µg/mL (at pH 
6.6; n = 18), and its apparent aqueous solubility in the presence of the various hydrotropes 
found as summarised in Table 1a-b (the coefficient of variation on the measured drug 
concentrations in all cases  0.5%). As has been noted previously (Jain 2008, Kim et al. 2010), 
the magnitude of the drug’s solubility enhancement is seen to increase with increasing 
hydrotrope concentration but the pattern of this increase varies from one hydrotrope to 
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another (see Figure 3). The range of the drug’s solubility enhancements obtained using 0.5 M 
hydrotrope vary from a modest 3-fold increase obtained with the addition of sodium p-
toluenesulfonate, through to a 470-fold increase obtained in the presence of 0.5 M sodium 
nicotinate. 
For some hydrotropes, the solubility enhancement that could be achieved was limited by the 
low aqueous solubility of the hydrotrope. Benzamide, for example, could only be tested at 0.1 
M, while sodium benzenesulfonate and sodium gentisate could be tested only up to 0.9 M. 
A subjective assessment of the solubility enhancement data shown in Table 1a-b, coupled 
with a simple inspection of the structures of the experimentally screened hydrotropes (Figure 
2) served to confirm some of the observations recorded by earlier researchers, but also 
revealed some anomalous behaviour. 
Kim et al. (Kim et al. 2010) have observed that the hydrogen bonding capacity of a hydrotrope 
is key to its efficacy in solubilising drugs, and Lee et al.(Lee et al. 2003)  have observed too 
that the polarity of a hydrotrope is an important determinant of solubility enhancement, with 
compounds that have a greater proportion of polar groups affording a lesser enhancement of 
drug solubility. Concordantly, we see here that the solubility of indomethacin is increased 
roughly 260-fold increase in the presence of sodium benzoate, but only increased by around 
60-fold in the presence of the more polar sodium salicylate –  these two compounds differing 
in polarity as the result of an additional hydroxyl group in sodium salicylate (see Figure 2). 
Contrary to this view, however, we find that sodium gentisate – which is more polar than 
sodium salicylate (by virtue of a second hydroxyl group on the aromatic ring; Figure 2) exhibits 
a 90-fold increase in indomethacin solubility, which is therefore greater than, rather than less 
than the 60-fold increase seen for sodium salicylate. 
Lee et al. (Lee et al. 2003) also observed that the nature of a hydrotrope’s ring system can 
influence its drug solubility enhancement, and this too is noted here. We see, for example, 
that sodium nicotinate, which has a pyridine ring, shows a 470-fold increase in indomethacin 
solubility at a concentration of 0.5 M, whereas sodium benzoate, which has a phenyl ring, 
shows only a 260-fold at the same concentration. It would thus appear that, for indomethacin, 
at least, an aromatic heterocycle serves greater benefit than a carbocycle. 
From the data presented here we note too that – consistent with the data presented in Lee 
et al. (Lee et al. 2003) – sulfonates seem to be generally less effective as hydrotropes than 
carboxylates, with the solubility enhancement achieved with sodium benzenesulfonate much 
less than that achieved using the same concentration of sodium benzoate. In addition, we 
find that an increased fraction of sp3 carbon in the hydrophobe is beneficial (as per the 
findings reported by Kim et al. (Kim et al. 2010) and Lee et al. (Lee et al. 2003), with the 
solubility enhancement achieved with 0.1 M N,N-diethylnicotinamide greater than that 
achieved using the same concentration of the N,N-dimethyl compound, and this in turn 
greater than that achieved using the parent benzamide. 
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Given that the aqueous solubility of indomethacin varies with pH (Jain, 2008), and the fact 
that many of the hydrotropes studied here will change the solvent pH, one might suppose 
that the measured solubility enhancements of the drug would follow the pattern of pH 
change. A plot of the measured equilibrium drug solubility against hydrotrope solution pH, 
however, shows no clear pattern (see Supplementary Information, Figure S1). Whilst the 
solvent pH, therefore, will undoubtedly affect the drug’s aqueous solubility, as too will the 
use of counterions, the net enhancement to solubility is patently the result of several 
contributing factors. 
Taking the experimentally determined solubility enhancement data for each hydrotrope and 
interpolating the fitted curve will of course furnish predicted solubility enhancements for 
concentrations of hydrotrope that have not been tested but such modelling has limited utility 
given that it is confined to prediction for a single hydrotrope, and affords no insight into the 
properties of hydrotropes that influence drug solubilisation. An ANN trained to predict the 
solubility enhancements using hydrotrope chemical properties as inputs, however, provides 
the perfect means to determine the nature of the key determinants, and also allows a 
quantitative assessment of their relative importance.  
3.2 In-silico screening of potential hydrotropes for indomethacin 
Experimental data from the drug solubility studies described above were used as the target 
output to train an artificial neural network (ANN), with input data furnished by the 
corresponding normalised hydrotrope concentrations, together with the physicochemical 
descriptors for the hydrotropes as given in Table 1a-b. The trained ANN was subsequently 
interrogated to explore the relative importance of the input parameters in determining drug 
solubility enhancement, and then also used for in-silico screening of untested hydrotrope 
systems in a search for compounds that might afford a greater enhancement of indomethacin 
solubility. 
The ANN developed was found to give highly accurate predictions of indomethacin solubility 
in the presence of hydrotropes at different concentrations, with residuals randomly 
scattered, and typically lying in the range ± 0.1 mg.mL-1 (see Supplementary Information, 
Figure S2). The correlation of the observed and predicted drug solubility data (Figure 4) was 
high (r2 = 0.998), with the slope of the regression line insignificantly different from unity and 
the intercept insignificantly different from zero (p < 0.001 in both cases). 
A quantitative assessment of the relative importance of the various hydrotrope 
physicochemical properties in determining the extent of the solubility enhancement for 
indomethacin was afforded through an interrogation of the sum of squared connection 
weights for the outgoing connections from the input neurons (Richardson et al. 1997). By this 
means, it was found that the order of importance of the input parameters was: hydrogen 
bond acceptor count > hydrotrope concentration > melting point > complexity > pKa > heavy 
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atom count > hydrogen bond donor count > F (ionised) > log P > species (acidic, basic or 
neutral). 
As a means to explore the landscape of hydrotrope properties more fully – and by such means 
then to determine the set of features required in the “ideal” hydrotrope for indomethacin – 
the trained ANN was subsequently used in in-silico screening of a set of 16 new compounds 
which were manually selected as potential hydrotropes that might afford a greater 
enhancement of indomethacin solubility (see Table 2 and Figure 5). The same set of 10 
physicochemical descriptors as used in the ANN training was employed here for prediction of 
the solubility enhancement of these 16 compounds. 
The results of the solubility enhancement of indomethacin varied quite widely among these 
in-silico screened hydrotropes, with 0.5 M p-toluic acid and 0.5 M p-coumaric acid predicted 
to give only 93-fold and 106–fold enhancements, and 0.5 M picolinic acid predicted to give an 
impressive 800-fold enhancement. Caffeine – the external test compound included to test the 
ANN’s generalisation – was predicted to give an extremely poor solubility enhancement for 
indomethacin (0.02 mg/mL at 0.1 M) and the level of enhancement was subsequently 
determined by experiment to be gratifyingly close to this value, at 0.032 ± 0.001 µg/mL.  
Of the 16 compounds included in this initial test screening, it is pertinent to note that 
resorcinol – a compound that has been extensively studied and shown to be a very good 
hydrotropic agent (Abdelbary et al. 2016, Lee et al. 2003, Roy and Moulik 2002) – was 
predicted here to give a solubility enhancement for indomethacin of the order of 2000-fold. 
On the basis of the ANN connection weight interrogation and the in-silico screening of the 16 
test hydrotropes, the “ideal” hydrotrope for indomethacin was identified as a low complexity 
compound having a pyridine ring as hydrophobe, with an alkyl-substituted amide moiety, and 
a low hydrogen bond acceptor count. 
With these criteria, a search was then made for compounds that were commercially available, 
and which could be tested empirically as potential new hydrotropes for indomethacin. A 
suitable candidate was found in pyridoxine (vitamin B6; Figure 6) – for which our trained ANN 
predicted 7.78 mg/mL indomethacin dissolved using a hydrotrope concentration of 0.5 M. 
Given that the reported aqueous solubility of this compound is just 220 mg/mL (Kim et al. 
2015), its ability to enhance the apparent aqueous solubility of indomethacin was determined 
using concentrations of 0.1 M and 0.5 M only. The apparent aqueous solubility of the 
indomethacin with these hydrotrope levels was determined as 0.39 ± 0.04 mg/mL, and 2.18 
± 0.27 mg/mL (n = 3), respectively. Fully in accord with our predictions, therefore, we find 
that pyridoxine does indeed provide a very good hydrotrope for indomethacin, giving a 130-
fold solubility enhancement at 0.1 M – which is comparable with the previous best of a 140-
fold enhancement achieved using the same concentration of sodium nicotinate - and an 
impressive 727-fold enhancement at 0.5 M – which exceeds the previous best of a 470-fold 
enhancement achieved using 0.5 M sodium nicotinate. 
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4. Conclusions 
The in-vitro and in-silico studies presented here demonstrate that hydrotropy offers promise 
as a device to increase the apparent aqueous solubility of poorly water-soluble drugs like 
indomethacin. The ANN trained on the basis of the reported indomethacin/hydrotrope 
solubilisation data was utilised not only to predict – with high accuracy – the increase in the 
apparent aqueous solubility of the indomethacin, but also allowed an informative exploration 
of the relative importance of various physicochemical properties of the hydrotropes in 
providing such enhancements. The designed ANN was also shown to be valuable in identifying 
new prospective hydrotropes for indomethacin. 
In our ongoing research, we aim to extend these studies by taking the hydrotrope-enhanced 
aqueous solubilities for a range of different drugs, and then using these data to develop a 
more general ANN that can be employed to predict solubility data for a range of 
drug/hydrotrope systems. Generating the experimental data needed to train such an ANN 
will of course require significant time and effort, but once the ANN has been trained 
successfully, it will then be possible to reduce the future need for extensive trial-and-error 
laboratory testing of these systems, and would thereby reduce the costs and time involved in 
drug formulation development.  
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Figure 1: Chemical structure of indomethacin 
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Figure 2: Hydrotropes tested experimentally: sodium nicotinate (A), sodium benzoate (B), sodium 
salicylate (C), sodium gentisate (D), nicotinamide(E), benzamide (F), N,N-dimethylbenzamide (G) N,N-
diethylnicotinamide (H), sodium benzenesulfonate (I) sodium p-toluenesulfonate (J) 
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Figure 3: Apparent aqueous solubility of indomethacin as a function of hydrotrope concentration (the 
data for sodium nicotinate, sodium benzoate, nicotinamide and sodium p-toluenesulfonate are 
plotted as filled circles, open circles, filled triangles and open diamonds, respectively)  
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Figure 4: Correlation between the observed and predicted hydrotrope enhanced apparent aqueous 
solubility of indomethacin (training set data plotted as circles and the cross-validation data as 
triangles) 
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Figure 5: In-silico tested potential hydrotropes: p-toluic acid (A), picolinic acid (B), p-hydroxybenzoate 
(C), guaiacol (D), catechol (E), 3-methylcatechol (F), 4-methylcatechol (G), 4-nitrolcatechol (H), 
resorcinol (I), 4-methylresorcinol (J), isophthalic acid (K), vanillin (L), vanillic acid (M), caffeine (N), p-
coumaric acid (O), and ferrulic acid (P). 
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Figure 6: Pyridoxine  
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Table 1a: ANN training and cross-validation datasets. 
Hydrotrope 
name 
Input Output/
target 
 
[H
T] 
(
M
) 
MP
† 
(oC
) 
log
P† 
pK
a† 
HB
D†† 
HB
A†† 
HA
C†† 
Comple
xity†† 
F 
(ionis
ed) 
Spec
ies 
[IND] 
(mg/mL) 
%
CV 
Tr
ai
n
in
g 
se
t 
Salicylic acid 
 
0.
1 
 
 
15
8 
 
 
2.2
6 
 
 
2.9
7 
 
 
2 
 
 
3 
 
 
10 
 
 
133 
 
 
1 
 
 
-1 
0.04 ± 
0.00 
0.
13 
0.
5 
0.17 ± 
0.01 
0.
06 
1.
3 
1.14 ± 
0.08 
0.
07 
1.
7 
2.17 ± 
0.12 
0.
06 
Gentisic acid 
 
0.
1 
 
 
19
9.5 
 
 
1.7
4 
 
 
2.9
5 
 
 
3 
 
 
4 
 
 
11 
 
 
157 
 
 
1 
 
 
-1 
0.05 ± 
0.00 
0.
08 
0.
5 
0.26 ± 
0.02 
0.
08 
0.
9 
0.64 ± 
0.05 
0.
08 
Benzoic acid 
 
0.
1 
 
 
12
2.4 
 
 
1.8
7 
 
 
4.1
9 
 
 
1 
 
 
2 
 
 
9 
 
 
104 
 
 
0.996 
 
 
-1 
0.20 ± 
0.01 
0.
05 
0.
5 
0.79 ± 
0.20 
0.
25 
1.
3 
3.04 ± 
0.67 
0.
22 
1.
7 
5.87 ± 
1.00 
0.
17 
Nicotinic 
acid 
 
0.
1 
 
 
23
6.6 
 
 
0.3
6 
 
 
4.7
5 
 
 
1 
 
 
3 
 
 
9 
 
 
114 
 
 
0.986 
 
 
-1 
0.42 ± 
0.01 
0.
02 
0.
5 
1.41 ± 
0.10 
0.
07 
1.
3 
4.11 ± 
0.61 
0.
15 
1.
7 
5.44 ± 
0.45 
0.
08 
Nicotinamid
e 
 
0.
1 
 
 
13
0 
 
 
- 
0.3
7 
 
 
3.3
5 
 
 
1 
 
 
2 
 
 
9 
 
 
114 
 
 
0.001 
 
 
1 
0.07 ± 
0.00 
0.
06 
0.
5 
0.33 ± 
0.02 
0.
06 
1.
3 
1.23 ± 
0.13 
0.
01 
1.
7 
1.55 ± 
0.32 
0.
21 
N,N-
diethylnicoti
namide 
 
0.
1 
 
 
25 
 
 
0.3
3 
 
 
3.5
0 
 
 
0 
 
 
2 
 
 
12 
 
 
166 
 
 
0.001 
 
 
1 
0.07 ± 
0.00 
0.
03 
0.
5 
0.31 ± 
0.02 
0.
06 
1.
5 
2.20 ± 
0.37 
0.
17 
2.
0 
3.73 ± 
0.49 
0.
13 
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Table 1b: ANN training and cross-validation datasets. 
Hydrotrope 
name 
Input Output/
target 
 
[H
T] 
(
M
) 
MP
† 
(oC
) 
log
P† 
pK
a† 
HB
D†† 
HB
A†† 
HA
C†† 
Comple
xity†† 
F 
(ionis
ed) 
Spe
cies 
[IND] 
(mg/mL) 
%
CV 
Tr
ai
n
in
g 
se
t 
N,N-
dimethylbe
nzamide 
 
0.
1 
 
 
44 
 
 
0.6
2 
 
 
0.0
0 
 
 
0 
 
 
1 
 
 
11 
 
 
137 
 
 
0 
 
 
0 
0.01 ± 
0.00 
0.
40 
0.
5 
0.15 ± 
0.00 
0.
03 
1.
2 
1.79 ± 
0.14 
0.
08 
1.
5 
3.52 ± 
0.34 
0.
10 
P-
toluenesulf
onic acid 
 
0.
1 
 
 
10
4.5 
 
 
1.7
0† 
 
 
- 
1.3
4 
 
 
1 
 
 
3 
 
 
11 
 
 
206 
 
 
1 
 
 
-1 
0.00 ± 
0.00 
0.
10 
0.
5 
0.01 ± 
0.00 
0.
10 
1.
3 
0.07 ± 
0.01 
0.
14 
1.
6 
0.16 ± 
0.01 
0.
06 
Benzenesulf
onic acid 
0.
1 
 
65 
 
0.0
0†† 
 
2.5
5 
 
1 
 
3 
 
10 
 
184 
 
1 
 
-1 
0.01 ± 
0.00 
0.
50 
0.
5 
0.14 ± 
0.03 
0.
21 
0.
9 
0.27 ± 
0.01 
0.
04 
Benzamide 0.
1 
12
9.1 
0.6
4 
0.0
0 
1 1 9 106 0 0 0.00 ± 
0.00 
0.
25 
C
ro
ss
-v
a
lid
at
io
n
 s
e
t 
Salicylic acid 0.
9 
15
8 
2.2
6 
2.9
7 
2 3 10 133 1 -1 0.49 ± 
0.02 
0.
04 
Benzoic acid 0.
9 
12
2.4 
1.8
7 
4.1
9 
1 2 9 104 0.996 -1 1.32 ± 
0.39 
0.
30 
Nicotinic 
acid 
0.
9 
23
6.6 
0.3
6 
4.7
5 
1 3 9 114 0.986 -1 2.69 ± 
0.28 
0.
10 
Nicotinamid
e 
0.
9 
13
0 
-
0.3
7 
3.3
5 
1 2 9 114 0.001 1 0.73 ± 
0.04 
0.
05 
N,N-
diethylnicot
inamide 
1.
0 
25 0.3
3 
3.5
0 
0 2 12 166 0.001 1 0.87 ± 
0.03 
0.
03 
N,N-
dimethylbe
nzamide 
0.
9 
44 0.6
2 
0.0
0 
0 1 11 137 0 0 0.69 ± 
0.06 
0.
09 
p-
toluenesulf
onic acid 
0.
9 
10
4.5 
1.7
0 
-
1.3
4 
1 3 11 206 1 -1 0.03 ± 
0.00 
0.
03 
Caffeine 0.
1 
23
6.2 
-
0.1
0 
10.
40 
0 3 14 293 1 1 0.03 ± 
0.00 
0.
04 
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Hydrotrope concentration [HT], melting point (MP), hydrogen bond donor count (HBD), hydrogen 
bond acceptor count (HBA), heavy atom count (HAC), indomethacin concentration ± standard 
deviation [IND ± SD], %CV, coefficient of variation 
† Obtained from EPI suiteTM (version 4.00) software  
†† obtained from the NCBI PubChem Database  (Kim et al. 2015) 
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Tables 2: Physicochemical properties of in-silico tested hydrotropes and the corresponding predicted 
apparent aqueous solubility of indomethacin (IND)*  
Potential 
hydrotrope 
(0.5 M 
concentration) 
MP 
(oC) 
logP pKa HBD HBA HAC Complexity F 
(ionised) 
pH 6.6 
Species Predicted 
IND 
solubility 
(mg/mL) 
p-toluic acid 179.6 2.27 4.37 1 2 10 123 0.994 -1 0.28 
Picolinic acid 136.5 0.72 5.39 1 3 9 114 0.942 -1 2.44 
Isophthalic acid 347.0 1.66 3.7 2 4 12 179 0.999 -1 0.45 
Vanillin 81.5 1.21 7.4 1 3 11 135 0.137 -1 7.73 
Vanillic acid 211.5 1.43 4.51 2 4 12 168 0.992 -1 0.74 
Guiacol 32.0 1.32 9.98 1 2 9 83 0.000 -1 7.61 
Resorcinol 111.0 0.8 9.32 2 2 8 64.9 0.002 -1 7.76 
4-
Methylresorcinol 
106.0 1.6 9.77 2 2 9 92.9 0.001 -1 7.73 
Catechol 105.0 0.88 9.45 2 2 8 62.9 0.001 -1 7.75 
4-
Methylcatechol 
65.0 1.37 9.55 2 2 9 92.9 0.001 -1 7.68 
3-
Methylcatechol 
68.0 1.8 9.59 2 2 9 92.9 0.001 -1 6.64 
4-Nitrolcatechol 175.0 1.66 9.17 2 4 11 155 0.212 -1 7.70 
Ferrulic acid 173.0 1.51 4.58 2 4 14 224 0.991 -1 0.42 
p-coumaric acid 214.0 1.46 4.64 2 3 12 178 0.989 -1 0.32 
p-
hydroxybenzoate 
214.5 1.58 4.54 1 3 10 125 0.991 -1 0.71 
* Abbreviations used are as given in Table 1a-b 
 
 
 
 
